PreveCeutical Medical (Seite 35)
eröffnet am 04.10.18 20:07:39 von
neuester Beitrag 06.05.24 23:44:20 von
neuester Beitrag 06.05.24 23:44:20 von
Beiträge: 879
ID: 1.289.874
ID: 1.289.874
Aufrufe heute: 1
Gesamt: 30.241
Gesamt: 30.241
Aktive User: 0
ISIN: CA74141E1043 · WKN: A2DU8Q
0,0160
EUR
0,00 %
0,0000 EUR
Letzter Kurs 18:58:07 Lang & Schwarz
Neuigkeiten
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,0500 | +112,88 | |
| 1,2200 | +44,38 | |
| 4,9400 | +40,34 | |
| 13,760 | +37,85 | |
| 2,8200 | +31,78 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,3680 | -13,53 | |
| 0,6450 | -14,00 | |
| 0,5051 | -14,39 | |
| 27,53 | -15,29 | |
| 2,0500 | -28,32 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 69.186.945 von Smuudo am 30.08.21 15:01:57Ja die BIG NEWS kommen noch. Ich warte auf Sol-Gel und Opioid Alternative sowie die Eintragung der Patente. Dann kann es hier endlich losgehen. Ich denke es ist trotzdem ratsam sich jetzt richtig einzudecken, da die Maße an Aktien nachher nicht mehr zu diesem Preis gekauft werden kann. Ich bin jetzt bei knapp 1 Mio Aktien
Antwort auf Beitrag Nr.: 69.186.768 von jetset0711 am 30.08.21 14:43:55Super Danke! 👍🏻 Ist aber jetzt nix dabei was umhaut! 😉
Short Interest in PreveCeutical Medical Inc. (OTCMKTS:PRVCF) Expands By 36,600.0%
Posted by ABMN Staff on Aug 26th, 2021
PreveCeutical Medical logoPreveCeutical Medical Inc. (OTCMKTS:PRVCF) saw a large growth in short interest in the month of August. As of August 13th, there was short interest totalling 36,700 shares, a growth of 36,600.0% from the July 29th total of 100 shares. Based on an average daily trading volume, of 235,600 shares, the days-to-cover ratio is presently 0.2 days.
PRVCF remained flat at $$0.02 during trading on Thursday. 204,420 shares of the company’s stock traded hands, compared to its average volume of 304,936. The business’s fifty day moving average is $0.02. PreveCeutical Medical has a 12 month low of $0.01 and a 12 month high of $0.04.
Posted by ABMN Staff on Aug 26th, 2021
PreveCeutical Medical logoPreveCeutical Medical Inc. (OTCMKTS:PRVCF) saw a large growth in short interest in the month of August. As of August 13th, there was short interest totalling 36,700 shares, a growth of 36,600.0% from the July 29th total of 100 shares. Based on an average daily trading volume, of 235,600 shares, the days-to-cover ratio is presently 0.2 days.
PRVCF remained flat at $$0.02 during trading on Thursday. 204,420 shares of the company’s stock traded hands, compared to its average volume of 304,936. The business’s fifty day moving average is $0.02. PreveCeutical Medical has a 12 month low of $0.01 and a 12 month high of $0.04.
Dual Gene Therapy
TARGETING TYPE 2 DIABETES AND OBESITY
Over five years of multi-disciplinary research, Dr. Parekh’s team has collectively generated convincing results in models of this disease, using Smart siRNA and a Tissue Targeted Bio-responsive Carrier System. This program paves the way for preclinical evaluation of proprietary chemistry toward the single gene target implicated in type 2 diabetes and obesity, thereby reducing capacity to store fat, reversing obesity, fatty liver disease, and possibly curing the disease rather than just managing it.
“With diabetes, over-production of a particular protein molecule has been identified and purposed to be responsible for the key drivers of diabetes and obesity, starting patient on an inevitable journey of significant co-morbidity and increased rates of mortality.
PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels; this would in turn help our cells to absorb glucose, thus reducing blood sugar levels and prevent the body from storing excessive fat from our diet. Thus gene-silencing does not represent a mere management for diabetes and obesity, it represents the potential for a bona fide cure or, in cases where patients have a pre-disposition to diabetes or are in the pre-diabetes state, it can be applied as a ‘PreveCeutical’ to halt progress to the full-blown disease.
This is not merely theoretical. Five years of painstaking work has gone into this initiative and management has already taken this research through the proof-of-concept stage in cellular models of diabetes and obesity.” – Chief Research Officer: Dr. Harry Parekh, PhD, MRPharmS
TARGETING TYPE 2 DIABETES AND OBESITY
Over five years of multi-disciplinary research, Dr. Parekh’s team has collectively generated convincing results in models of this disease, using Smart siRNA and a Tissue Targeted Bio-responsive Carrier System. This program paves the way for preclinical evaluation of proprietary chemistry toward the single gene target implicated in type 2 diabetes and obesity, thereby reducing capacity to store fat, reversing obesity, fatty liver disease, and possibly curing the disease rather than just managing it.
“With diabetes, over-production of a particular protein molecule has been identified and purposed to be responsible for the key drivers of diabetes and obesity, starting patient on an inevitable journey of significant co-morbidity and increased rates of mortality.
PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels; this would in turn help our cells to absorb glucose, thus reducing blood sugar levels and prevent the body from storing excessive fat from our diet. Thus gene-silencing does not represent a mere management for diabetes and obesity, it represents the potential for a bona fide cure or, in cases where patients have a pre-disposition to diabetes or are in the pre-diabetes state, it can be applied as a ‘PreveCeutical’ to halt progress to the full-blown disease.
This is not merely theoretical. Five years of painstaking work has gone into this initiative and management has already taken this research through the proof-of-concept stage in cellular models of diabetes and obesity.” – Chief Research Officer: Dr. Harry Parekh, PhD, MRPharmS
Non-Addictive Analgesic
ENGINEERING NON-ADDICTIVE ANALGESIC PEPTIDES FOR PAIN MANAGEMENT
PreveCeutical Medical Inc., and partner UniQuest Pty Ltd have signed a research and option agreement proposing to expand the use of their disulphide linker technology to develop non-addictive analgesics for moderate-to-severe pain.
This Research and Development program, led by Dr. Harry Parekh in-conjunction with his fellow collaborators at The University of Queensland’s School of Pharmacy, involves peptide library synthesis, pharmacological evaluation, alongside pharmacokinetic assessment and efficacy determinations in appropriate animal models of pain and inflammation, and may encompass either party’s intellectual property and product line and other pharmaceutical offerings that may fall within the peptide Research and Development program.
Dr. Parekh commented “This is a very exciting and important program as we focus on engineering a novel class of drugs derived from our very own endogenous pain pathways, for example when pain and inflammatory insults occur. Our preliminary work has highlighted that by using our proprietary linker technology we can enhance stability while maintaining, and in some cases enhancing the potency of lead bioactives. Having PreveCeutical on board will accelerate our current program, allowing us to rapidly expand and screen the bioactive library, taking the most promising candidates through to efficacy and pharmacokinetic evaluation.
Peptides are currently being used to target an array of disease indications including metabolic disorders, pain, cancers, cardiovascular and infectious diseases. The therapeutic peptide market is projected to undergo considerable expansion in the foreseeable future as technologies to enhance their stability and bioavailability emerge.
ENGINEERING NON-ADDICTIVE ANALGESIC PEPTIDES FOR PAIN MANAGEMENT
PreveCeutical Medical Inc., and partner UniQuest Pty Ltd have signed a research and option agreement proposing to expand the use of their disulphide linker technology to develop non-addictive analgesics for moderate-to-severe pain.
This Research and Development program, led by Dr. Harry Parekh in-conjunction with his fellow collaborators at The University of Queensland’s School of Pharmacy, involves peptide library synthesis, pharmacological evaluation, alongside pharmacokinetic assessment and efficacy determinations in appropriate animal models of pain and inflammation, and may encompass either party’s intellectual property and product line and other pharmaceutical offerings that may fall within the peptide Research and Development program.
Dr. Parekh commented “This is a very exciting and important program as we focus on engineering a novel class of drugs derived from our very own endogenous pain pathways, for example when pain and inflammatory insults occur. Our preliminary work has highlighted that by using our proprietary linker technology we can enhance stability while maintaining, and in some cases enhancing the potency of lead bioactives. Having PreveCeutical on board will accelerate our current program, allowing us to rapidly expand and screen the bioactive library, taking the most promising candidates through to efficacy and pharmacokinetic evaluation.
Peptides are currently being used to target an array of disease indications including metabolic disorders, pain, cancers, cardiovascular and infectious diseases. The therapeutic peptide market is projected to undergo considerable expansion in the foreseeable future as technologies to enhance their stability and bioavailability emerge.
Trading Spotlight
BSV Peptide Program
TARGETING CANCER PROGRESSION
PreveCeutical, and research partner Uniquest, are currently screening peptides isolated from Caribbean Blue Scorpion venom across some of the most aggressive diseases where there exists unmet clinical need, such as cancer. There are numerous research papers in the public domain which show the anecdotal findings and efficacy of venom peptides taken through the proven route of administration on cancerous cells/tumours.
Recently the Company announced positive results from the preliminary screening of key peptides from its scorpion venom-derived peptide research and development program that is expected to enable PreveCeutical to generate Nature Identical™ peptide therapeutics intended for therapeutic applications. PreveCeutical’s initial focus is to understand the activities of such peptides in cell-based brain cancer models.
Through preliminary screening in a glioblastoma cell-based assay, PreveCeutical’s research team has successfully identified four lead peptides that inhibit the activity of a target protein implicit in the progression of certain aggressive brain cancers.
Further, the re-designed and synthesized peptides were found to be equally or more potent in the cell-based activity assay when compared to another scorpion peptide, Chlorotoxin. A series of more comprehensive screening assays are underway in the final stage of the Peptide Program, to allow the Company to develop a more detailed understanding of the activities of the peptides in progressively complex cell-based brain cancer models.
TARGETING CANCER PROGRESSION
PreveCeutical, and research partner Uniquest, are currently screening peptides isolated from Caribbean Blue Scorpion venom across some of the most aggressive diseases where there exists unmet clinical need, such as cancer. There are numerous research papers in the public domain which show the anecdotal findings and efficacy of venom peptides taken through the proven route of administration on cancerous cells/tumours.
Recently the Company announced positive results from the preliminary screening of key peptides from its scorpion venom-derived peptide research and development program that is expected to enable PreveCeutical to generate Nature Identical™ peptide therapeutics intended for therapeutic applications. PreveCeutical’s initial focus is to understand the activities of such peptides in cell-based brain cancer models.
Through preliminary screening in a glioblastoma cell-based assay, PreveCeutical’s research team has successfully identified four lead peptides that inhibit the activity of a target protein implicit in the progression of certain aggressive brain cancers.
Further, the re-designed and synthesized peptides were found to be equally or more potent in the cell-based activity assay when compared to another scorpion peptide, Chlorotoxin. A series of more comprehensive screening assays are underway in the final stage of the Peptide Program, to allow the Company to develop a more detailed understanding of the activities of the peptides in progressively complex cell-based brain cancer models.
Cannabinoid Sol-Gel Delivery
NOSE-TO-BRAIN DELIVERY OF THERAPEUTIC CANNABINOIDS
Developing the first, sustained-release, cannabinoid-based nose-to-brain delivery system that will provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders. Our proprietary nasal formulations will also be designed to be universally-patient friendly, meaning formulations that can be used in children and adults alike.
Sol-gels are taken via nasal administration and rapidly gel upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This effectively bypasses the stomach and intestines - eliminating first pass metabolism - and may dramatically improve bioavailability - even compared to nasal sprays and other newer delivery systems. Additionally, the gel stays in the nasal passages, slowly releasing the cannabinoid while keeping it active for up to seven days. The ease of application and its long-lasting effects may be attractive for patients when compared to other delivery systems.
COVID-19 CBD SOL-GEL PROGRAM
PreveCeutical elected to extend this program in July 2020 to address the current COVID-19 pandemic. Under this extension, a nasal formulation incorporating a cannabinoid extract has been created. This formulation is based on reports by independent researchers who identified this extract as having anti-inflammatory properties and the potential to reduce the ability of SARS-CoV-2 to infect mucosa tissue.
We completed this development in November 2020, and PreveCeutical has filed a provisional patent. The Company will be looking to commercialize this formulation as a nasally administered treatment for COVID- 19 caused by SARS-CoV-2 infection.
PreveCeutical has also retained Versitat, a global clinical research organization, to assist with the clinical trial process. They have developed the roadmap, and clinical trial planning is underway.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.
NEXT STEPS
PreveCeutical now plans to begin exploratory discussions with pharmaceutical and biotechnology companies developing therapies for neurological disorders, that are seeking a targeted nose-to-brain drug delivery system in connection with same, with the intention of forming a partnership for the co-development of PreveCeutical's soluble gel.
"Sol-gel technology has certainly shown significant promise in laboratory testing at this point. eventually, I would like to see this proprietary technology be successfully applied to a drug which could be targeted for CNS delivery at the right time, we would welcome an opportunity to work with a pharmaceutical or biotechnology company to co-develop the Sol-Gel and sol-gel Applicator to be used in pharmaceutical and therapeutic products." – Chief Science Officer: Dr. Mak Jawadekar, PhD
NOSE-TO-BRAIN DELIVERY OF THERAPEUTIC CANNABINOIDS
Developing the first, sustained-release, cannabinoid-based nose-to-brain delivery system that will provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders. Our proprietary nasal formulations will also be designed to be universally-patient friendly, meaning formulations that can be used in children and adults alike.
Sol-gels are taken via nasal administration and rapidly gel upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This effectively bypasses the stomach and intestines - eliminating first pass metabolism - and may dramatically improve bioavailability - even compared to nasal sprays and other newer delivery systems. Additionally, the gel stays in the nasal passages, slowly releasing the cannabinoid while keeping it active for up to seven days. The ease of application and its long-lasting effects may be attractive for patients when compared to other delivery systems.
COVID-19 CBD SOL-GEL PROGRAM
PreveCeutical elected to extend this program in July 2020 to address the current COVID-19 pandemic. Under this extension, a nasal formulation incorporating a cannabinoid extract has been created. This formulation is based on reports by independent researchers who identified this extract as having anti-inflammatory properties and the potential to reduce the ability of SARS-CoV-2 to infect mucosa tissue.
We completed this development in November 2020, and PreveCeutical has filed a provisional patent. The Company will be looking to commercialize this formulation as a nasally administered treatment for COVID- 19 caused by SARS-CoV-2 infection.
PreveCeutical has also retained Versitat, a global clinical research organization, to assist with the clinical trial process. They have developed the roadmap, and clinical trial planning is underway.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.
NEXT STEPS
PreveCeutical now plans to begin exploratory discussions with pharmaceutical and biotechnology companies developing therapies for neurological disorders, that are seeking a targeted nose-to-brain drug delivery system in connection with same, with the intention of forming a partnership for the co-development of PreveCeutical's soluble gel.
"Sol-gel technology has certainly shown significant promise in laboratory testing at this point. eventually, I would like to see this proprietary technology be successfully applied to a drug which could be targeted for CNS delivery at the right time, we would welcome an opportunity to work with a pharmaceutical or biotechnology company to co-develop the Sol-Gel and sol-gel Applicator to be used in pharmaceutical and therapeutic products." – Chief Science Officer: Dr. Mak Jawadekar, PhD
🔥🔥🔥 ✅✅✅✅
Na was ist denn heute passiert? Über 30% abwärts! 🤷🏼♂️
Antwort auf Beitrag Nr.: 69.130.463 von wasi1970 am 24.08.21 07:29:20Kerosin wird aufgefüllt 😅 warte schon fast 3 Jahre
Durchsuchen
